Trials / Recruiting
RecruitingNCT06026111
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the feasibility and effects of 12-week exercise training at different intensities among individuals with advanced lung cancer receiving immune checkpoint inhibitors. The names of the study interventions involved in this study are:
Detailed description
This single-center, two-armed, pilot randomized controlled research study will assess feasibility and compare immune activities, cardiorespiratory fitness, physical function, and immunotherapy-related adverse events, and patient-reported outcomes between three groups - high-intensity exercise, moderate-intensity exercise, and usual care. Participants in this study will be randomly assigned to one of three groups: * High-intensity interval training (HIIT) * Moderate-intensity continuous training (MICT) * Usual care (UC) The HIIT and the MICT groups will receive virtually supervised home-based exercise training three sessions per week for 12 weeks. The UC group will be asked not to change their baseline exercise behavior and will be offered to receive one of the exercise programs at the end of the initial 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | High-Intensity Interval Training (HIIT) | Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion. |
| BEHAVIORAL | Moderate-Intensity Continuous Training (MICT) | Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion. |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2023-09-06
- Last updated
- 2026-04-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06026111. Inclusion in this directory is not an endorsement.